Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapies had low proportions of Black patients enrolled, according to research presented at the 2021 ASH Annual Meeting. Lead author Samer Al Hadidi, MD, MSc, of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences in Little Rock, and collaborators examined the enrollment of Black Americans in these trials through a retrospective analysis. The seven pivotal trials included in the study evaluated the following drugs and ...
ASH Annual Meeting 2021 Conference Coverage
Advertisement
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Damon E. Houghton, MD, MS, of Mayo Clinic in Rochester, Minnesota, presented the data at the ASH Annual Meeting 2021.
This lack of benefit was seen in the entire study population.
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
Advertisement
